{
  "docId": "019de077-4649-72e2-aa45-017392de211d",
  "docSlug": "8a7a8508ae9537047e1aabcda9819db4",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 27 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 27,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "Includes a flow diagram of the trial phases and a table of baseline characteristics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-4649-72e2-aa45-017392de211d/13",
  "deckHref": "/decks/019de077-4649-72e2-aa45-017392de211d",
  "deckJsonHref": "/decks/019de077-4649-72e2-aa45-017392de211d.json",
  "deckAnchorHref": "/decks/019de077-4649-72e2-aa45-017392de211d#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.42,
        "x": 0.07,
        "y": 0.33
      },
      "kind": "diagram",
      "text": "Trial flow diagram showing Screening, Randomization, Double Blind (6 months), and Open Label Extension (12 months).",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "433d07fa-d273-4b9d-89d3-ba4503272c06",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.48,
        "x": 0.45,
        "y": 0.33
      },
      "kind": "list",
      "text": "Primary: Safety and tolerability, ALS-hallmark biomarkers TDP-43 and/or PgJ2. Secondary: ALSFRS-R, SVC, PROMIS-10, Complication Free Survival.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ae29e90-55cf-42e9-9af7-280292d97a9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.86,
        "x": 0.07,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "A randomized (2:1), placebo-controlled, double-blind, multi-center trial (NCT05357950), followed by an open-label extension. Enrolled ALS patients with disease duration of <30 months and upright slow vital capacity (SVC) ≥ 60%. Standard of care (SOC) allowed.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e120dd02-e23d-4b31-9b11-f3dd8ed8d8ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.48,
        "x": 0.45,
        "y": 0.75
      },
      "kind": "table",
      "text": "Well-Balanced Baseline Characteristics: ALSFRS-R at baseline (PrimeC 37.5, Placebo 37.5)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f390926-5281-4008-840a-a2d0afa0aac8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.07,
        "y": 0.08
      },
      "kind": "title",
      "text": "PARADIGM Phase 2b Trial Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca70c7ea-0565-4a1b-8503-c978c58e77eb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "e07a84b5-6b9c-4a7b-b8f3-26b3525e529a",
      "evidence": "Standardized representation of trial phases, endpoints, and baseline characteristics.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "5eda8f32-b05b-4081-b142-37763a2894eb",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck showcases the results of PrimeC's clinical trials, including improvements in motor performance, neuronal survival, and disease progression",
      "position": 2,
      "confidence": 0.9,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}